Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
about
Small G proteins in the cardiovascular system: physiological and pathological aspectsMitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.Deletion of low molecular weight protein tyrosine phosphatase (Acp1) protects against stress-induced cardiomyopathy.Rescue of cardiac leptin receptors in db/db mice prevents myocardial triglyceride accumulationAltered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutationsRapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryProtein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand SpecificityAdipose-specific deletion of Src homology phosphatase 2 does not significantly alter systemic glucose homeostasis.Homocysteine induces cardiomyocyte dysfunction and apoptosis through p38 MAPK-mediated increase in oxidant stress.Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?Hepatic Src homology phosphatase 2 regulates energy balance in mice.Src homology 2 domain-containing phosphatase 2 (Shp2) is a component of the A-kinase-anchoring protein (AKAP)-Lbc complex and is inhibited by protein kinase A (PKA) under pathological hypertrophic conditions in the heartCardiomyocyte-specific deletion of leptin receptors causes lethal heart failure in Cre-recombinase-mediated cardiotoxicity.Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.Cardiac Gab1 deletion leads to dilated cardiomyopathy associated with mitochondrial damage and cardiomyocyte apoptosisSHP-2 tyrosine phosphatase in human diseases.Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.The tyrosine phosphatase Shp2 (PTPN11) directs Neuregulin-1/ErbB signaling throughout Schwann cell development.Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.Distinct and overlapping functions of ptpn11 genes in Zebrafish development.Revisited and revised: is RhoA always a villain in cardiac pathophysiology?Cardiotoxicity associated with targeting kinase pathways in cancer.Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.Modeling RASopathies with Genetically Modified Mouse Models.RhoA protects the mouse heart against ischemia/reperfusion injuryNew insights into the molecular phenotype of eccentric hypertrophy.ROCKs cause SHP-wrecks and broken hearts.Shp shape: FAKs about hypertrophy.Protein tyrosine phosphatases in cardiac physiology and pathophysiology.αB-Crystallin interacts and attenuates the tyrosine phosphatase activity of Shp2 in cardiomyocytes under mechanical stress.Glaucoma pathogenesis and neurotrophins: Focus on the Molecular and Genetic basis for Therapeutic prospects.
P2860
Q27010607-6CB9133C-7178-42E8-81A3-01FED86F3020Q28296128-B9C9441A-F208-4018-B7CC-DA9E60525E50Q30032300-80EE8E9B-6972-4748-B722-4DE84866EAC1Q34001340-C76E5B48-30E6-44FF-8E82-00835B6F0204Q34400843-D825F67F-2570-4CFB-A1C5-BCC3ADC8B01EQ34611774-2282FB5D-F18F-4C1E-8A6B-37E2D8628D89Q34627120-0E789B78-CC69-42D5-86CD-30145505A6E8Q35039202-61B561C2-3002-48DB-AFE3-497581217E97Q35583091-1A267477-D957-4096-846E-C69AEEAA88ADQ35611046-D59A3A53-E12E-4BC7-8EE3-6D4965C6C630Q35803548-C89F0DEB-7442-4BBF-91FF-D04EFD4F4F10Q35837138-53F2767D-7C79-4A2F-B0E2-49077E9BBB32Q36025665-927D8254-16E8-4BA2-8020-C0D3C2B7B1C4Q36049875-65817C04-E589-4944-9931-CB11945E7F65Q36418877-7638D8DB-491A-4067-B3A8-09309343BA05Q36494881-DBC124E2-0981-4B59-A751-BDAEF0F8265CQ36510904-55E898FC-401E-4DB3-94F6-72144FDCDA91Q36839960-88C2CB82-AC63-420B-9825-4CD9C028CDE1Q37033644-66AE2079-AB03-4B43-A070-C090693B8D59Q37179335-5FBACE60-7229-44DB-8532-FF475130792AQ37186707-003D17C4-99A3-4383-90F8-228CEF7AD604Q37257055-845E0A84-7C5E-40AE-90C1-6A21621E6DFEQ37340867-7F1573A5-E94C-4CAC-84F1-591ABA8076E7Q37342975-A9C81CBE-41D6-43B6-B16A-6FAAB98F1096Q37353815-1E940D6F-0870-4FD4-94F8-57D71FFF0C8BQ37705054-8104A76D-3B2D-4104-8B4D-98C127149068Q37766125-3933E6AD-27E3-411D-B493-4BC170E0246BQ37823035-E5742C3D-AAE6-4397-9F5A-B3B027D1D13BQ38261370-CF6CE5EB-B3A2-4024-8AFC-3CC09336A684Q39031139-FFD867EC-7A37-4FA0-87E5-E026202DCB50Q42014677-5A79A7AE-9AC3-450B-BFF9-6B7DD02D7ADDQ42131608-88BD21C5-9C4C-4F57-B3AE-E507FF36124BQ42408788-4F4A37C0-E5ED-4725-8F0E-C945177AE685Q43149054-7A857C6B-D193-4A78-A95B-C34F63955412Q49356041-CDDFC004-CEDE-41D0-9EC3-3FCD06CCED27Q51719183-1F55EF75-1E47-4C90-B48C-4A71DF69CC8CQ52314492-F6243CB9-BFAC-484F-981A-1EA6D3C396DD
P2860
Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Deletion of Ptpn11 (Shp2) in c ...... e and RhoA signaling pathways.
@en
type
label
Deletion of Ptpn11 (Shp2) in c ...... e and RhoA signaling pathways.
@en
prefLabel
Deletion of Ptpn11 (Shp2) in c ...... e and RhoA signaling pathways.
@en
P2093
P2860
P1433
P1476
Deletion of Ptpn11 (Shp2) in c ...... e and RhoA signaling pathways.
@en
P2093
Aleksander Hinek
Benjamin G Neel
Darragh Cullen
Kendra K Bence
Maria I Kontaridis
Natalya Bodyak
Peter M Kang
Ronglih Liao
P2860
P304
P356
10.1161/CIRCULATIONAHA.107.728865
P407
P577
2008-03-03T00:00:00Z